Received Jan 21, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
Hair thinning; Nails deep groove; Nail overgrowth; This non-serious case was reported by a consumer and described the occurrence of hair thinning in a 62-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On 17-SEP-2025, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced hair thinning (Verbatim: Hair thinning), nail disorder (Verbatim: Nails deep groove) and nail growth increased (Verbatim: Nail overgrowth). The outcome of the hair thinning, nail disorder and nail growth increased were not resolved. It was unknown if the reporter considered the hair thinning, nail disorder and nail growth increased to be related to Shingrix. It was unknown if the company considered the hair thinning, nail disorder and nail growth increased to be related to Shingrix. Additional Information: GSK Receipt Date: 16-JAN-2026 Patient had been taking collagen for her skin, hair, and nails in hopes of improvement. Patient's symptoms included hair thinning and deep grooves with overgrowth in the nails. These symptoms were not treated. The batch number was not provided and a request for this information has been made.